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Over the last decade, the zebrafish (Danio rerio) has emerged as amodel organism for cardiovascular research. Zebrafishhave several
advantages over mammalian models. For instance, the experimental cost of using zebrafish is comparatively low; the embryos are
transparent, develop externally, and have high fecundity making them suitable for large-scale genetic screening. More recently,
zebrafish embryos have been used for the screening of a variety of toxic agents, particularly for cardiotoxicity testing. Zebrafish has
been shown to exhibit physiological responses that are similar tomammals after exposure tomedicinal drugs including xenobiotics,
hormones, cancer drugs, and also environmental pollutants, including pesticides and heavy metals. In this review, we provided a
summary for recent studies that have used zebrafish to investigate the molecular mechanisms of drug-induced cardiotoxicity. More
specifically, we focused on the techniques that were exploited by us and others for cardiovascular toxicity assessment and described
several microscopic imaging and analysis protocols that are being used for the estimation of a variety of cardiac hemodynamic
parameters.
1. Introduction
Zebrafish (Danio rerio) is a small tropical fish, native
to Southeast Asia and belongs to the minnow family
(Cyprinidae) of order Cypriniformes [1]. Over the last 30
years, zebrafish has emerged as a model for studying a variety
of human disease development [2]. The zebrafish genome is
fully sequenced and its resemblance to human genome is sur-
prisingly high with 87% similarity [3]. It is estimated that 70%
of the human genes have orthologue genes in the zebrafish
genome [1, 4]. As a result, many genes that are associated with
human diseases exist in zebrafish and mutations observed
in human patients can be modelled in this animal. The
high conservation of zebrafish gene sequence and functions
compared to humans further demonstrates how zebrafish can
be used to model human diseases including cardiovascular
conditions [3]. Besides high gene conservation, the utilization
of zebrafish as a model to study cardiovascular development
and related disease offers a variety of advantages including
optical transparency, rapid cardiovascular development, and
a cheaper cost when compared to other in vivomodels [5].
In addition to investigating gene function and modelling
a variety of human disease, zebrafish embryos have been
extensively used to study cardiotoxicity [6]. Cardiotoxicity
is defined as the toxicity that damages the heart muscle and
other cardiac tissues and/or disrupts the electrophysiology
of the heart. As a result of cardiotoxicity, the heart may
not be able to pump adequate blood throughout the body
[7]. If severe, cardiotoxicity may lead to cardiomyopathy
in other terms cardiac muscle dysfunction. Cardiotoxicity
might occur as a side effect of chemotherapeutical drugs or
might develop due to exposure to certain chemicals. Lately,
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zebrafish embryos were shown to be very useful in toxicology
studies, particularly to screen for developmental toxicants [8,
9] and environmental pollutants such as pesticides and heavy
metals as well as nanoparticles [10, 11]. Small molecules can
be added directly into the fish water within multiwell plates
and absorbed via diffusion by the fish. Alternatively, studied
agents can be injected directly into the yolk sac [12–15].
Zebrafish is an inexpensive/high throughput experimental
model that offers several benefits that include the following:
the quantity of the tested agents is reduced; the duration of
the experiments is shorter; and technical expertise required
for its evaluation is less intensive than that of an equivalent
study performed in the traditional animal model, mice [16–
18]. Furthermore, chemical libraries can be applied to a large
number of embryos to systematically screen for a phenotype
of interest.
Drug-induced cardiotoxicity is a leading factor for drug
withdrawals from the market and failure of clinical trials. The
major factor for this drug attrition is lack of efficacy or drug
safety [19–21]. Nowadays, the costs of bringing new drugs to
the market are very expensive and are continually increasing.
The costs are estimated to be higher than one billion USD
per drug [22]. Unexpectedly, this increase in costs does not
correlate well with an increased success rate in approving new
drugs. Only 10 % of drugs entering phase 1 trial get approved
by the United States Food and Drug Administration (FDA)
[19, 23]. To reduce the large cost of drug development, there is
a need to identify potential adverse drug responses (ADR) as
early as possible before entering clinical trials. Academic and
pharmaceutical industry researchers are showing an increas-
ing interest in the zebrafish model. Zebrafish is a model
that bridges cell culture assays (cost-effective but poor data
content) and mammalian models (expensive but high data
content) during the preclinical pipeline. The toxicity effects
reported from zebrafish-based experiments are considered
representative for higher vertebrates including humans.Thus,
its use provides a closer scenario to human biology than in
vitro systems.
In this review, we present the important findings from
recent studies that have exploited zebrafish in cardiotoxicity
assays. We first explain the basics of heart development in
zebrafish and the structure of the cardiovascular system in
zebrafish. The following section will discuss the zebrafish
cardiotoxicity assays. The last section will involve findings
from drug-induced cardiotoxicity and environmental ter-
atogen agent-induced cardiotoxicity. Furthermore, analyzing
abnormal cardiac morphologies, and disturbed blood circu-
lation in response to drugs will be highlighted.
2. Heart Development and Cardiovascular
Structure in Zebrafish
In zebrafish, the heart is located anteroventrally to the tho-
racic cavity between the operculum and the pectoral girdles
[27].The heart is contained in a silver-coloured membranous
sac, known as the pericardium. More specifically, within the
pericardium, there are four distinct chambers that comprise
the heart: the sinus venosus, the atrium, the ventricle, and
the outflow tract, called the bulbus arteriosus. However, the
fish heart is often referred to as being two-chambered, with
one atrium and one ventricle. Heart development starts very
early in zebrafish development [28]. At just 5 hours postfertil-
ization (hpf), cardiac progenitors (identified by fate-mapping
experiments) are present in the lateral marginal zones of the
cleavage stage embryo [29]. Following the gastrulation, cells
from the anterior lateral plate mesoderm migrate towards
the midline and differentiate into ventricular and atrial
cardiomyocytes [29].Heart tube formation occurs around 24-
hpf (Figure 1), at which point the embryo is still translucent,
and visualization of ongoing development is possible [30].
At 24-hpf, the heart tube starts to elongate and bends so
that the ventricle becomes anterior and the atrium becomes
posterior [29]. At this stage, a beating linear heart tube has
been formed to propel circulation throughout the body. This
movement precedes the looping of the heart, ballooning of
the chambers, and formation of the atrioventricular canal.
Looping ends around 48-hpf [29]. At 48-hpf, the heart
consists of a sinus venosus (the inflow tract that collects
blood from cardinal veins and delivers it to the atrium), one
atrium (a muscled cavity that receives deoxygenated blood
and delivers it to the ventricle), and one ventricle (receives
blood from the atrium and delivers it to the body via the
aorta). During this time, the bulbus arteriosus (a pear-shaped
chamber through which the blood leaves the heart) develops
[31, 32]. While the heart is forming, cells are rearranging
and beginning to communicate in a way that enables them
to begin to pump blood through the heart via contraction.
Major morphological events, heart developmental stages,
and genes governing heart development in zebrafish are
summarized in Figure 1.
3. Cardiotoxicity Evaluation in Zebrafish
3.1. Cardiac Function Assessment. Zebrafish embryo is a
commonly used animal model to investigate the teratogenic
effects of the drugs. For this purpose, the cardiovascular
function of the animals needs to be evaluated to reveal the
influence of exposure on the development of the cardiovas-
cular system as well as on the growth of the whole animal.
Simple assays that measure the heart rate currently lack
specificity. As such, a more direct evaluation of the cardiac
hemodynamic events is critical when zebrafish is used as
a robust tool in investigating drug-induced cardiotoxicity.
Here we describe microscopy imaging and analysis protocols
utilized to calculate a variety of hemodynamic parameters for
zebrafish embryos exposed to clinical drugs.
Testing teratogenicity of clinical drugs involves exposing
zebrafish embryos to desired concentrations. Due to small
size of the embryos, multiple well plates can be used making
it possible to test a high number of animals simultaneously
[12, 13, 33]. Drug exposure usually begins around 5-hpf,
corresponding to late blastula/early gastrula stages and ends
at 96-hpf, where most organs are fully developed [34]. In
addition to analyzing organ morphologies, blood circulation
(hemodynamics) in the exposed animals can also be investi-
gated [35]. Such hemodynamic evaluation enables revealing
whether the tested drug affects the whole cardiovascular
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Figure 1: Overview of zebrafish heart development. By 14 hpf, cardiac progenitors have emerged from the anterior lateral plate mesoderm.
These cardiac precursors migrate and fuse at the midline to form a cone structure by 19 hpf. After one day of development, a beating linear
heart tube has formed to propel circulation through the body. Cardiac chambers are clearly demarcated and looping has completed after
two days of development.VM, ventricle myocardium; AM, atrium myocardium; EC, endocardium; (upper panel) stage of development
and hour postfertalisation, hpf, and (lower panel) genes that regulate the developmental processes. Gata5, Transcription factor required
during cardiovascular development; Hand2, Heart AndNeural Crest Derivatives Expressed 2;Tbx20, T-Box Transcription Factor; Smarcd3,4,
SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily D, Member 3and 4; CTR1, copper transporter;
Cdc37, Cell Division Cycle 37; RTF1, Paf1, LEO1, RNA Polymerase II Complex Component.
system, which in turn might affect the development of other
systems. For hemodynamic evaluation, the most calculated
parameters are heartbeat, cardiac output, fractional area
change, fractional shortening, and vascular blood flow veloc-
ities [36]. These evaluations can be done by analyzing the
embryos under an inverted or a stereo brightfield microscope
[37]. In more advanced applications, novel techniques like
computational fluid dynamics or particle image velocime-
try can also be used for detailed hemodynamic analysis
[38, 39].
The functional analysis involves quantification of the
pumping efficiency of the heart, whereas structural anal-
ysis involves precise measurement of heart chamber sizes.
These efforts necessitate the utilization of advanced fast
imaging techniques like time-lapse microscopy, fluorescent
microscopy, and micro-computed tomography. Determina-
tion of ventricular wall speeds is important formodelling car-
diac muscle conditions such as cardiomyopathy on zebrafish.
Levels of wall velocities are about 200–300𝜇m/sec for 2 to 5
days postfaveolization (dpf) embryos [37].Therefore, movies
should be recorded at high speeds and image analysis is
performed on these videos to find ventricular wall speeds
and heart rate. Alternatively, a variety of software application
can be used to extract the heart rate from beating heart
recordings automatically. The first commercially available
zebrafish tracking equipment was the ZebraBox/ZebraLab
(ViewPoint, France). The system consists of a box with an
infrared light source and a camera and it is capable of
recording movies with 100 frames per second. The ZebraLab
software controls the box and analyzes the swimming activity
of the larvae. The infrared light source allows for behavioural
monitoring in the dark, as the fish cannot see infrared light
[40]. Initially our laboratory used the ZebraBox to analyze
larval behaviour,measuring swimming distance, and velocity.
However, that initial version of ZebraLab had very limited
flexibility with respect to off line data analysis and did not
permit analysis of externally recorded movies of zebrafish
movement. Current versions of the ZebraBox and the soft-
ware have been significantly upgraded. The system now has
a fully flexible software platform and is capable of analyzing
recorded data retrospectively. The aim of the software is to
provide information on several cardiac parameters including
the heartbeat, blood flow, and vessel diameter variations
from a zebrafish high speed video. To evaluate the blood
flow, the algorithm determines the correlation between two
successive frames (Figure 2). The displacement between the
current frame and the best correlated area in the next frame
represent the global movement of the blood cells. The heart
beat is evaluated by measuring the number of oscillations
of the blood flow. To perform the best evaluation, there is
an automatic detection of the local minimal value of the
first and the last oscillation in the blood flow axis. These
values are represented by a black star in the blood flow axis
[41]. Determination of cell speed is important for evaluating
flow rate for the vessels and estimating the shear stress levels
acting on the endothelial cells lining the vessel wall (i.e., shear
stress is the frictional force on the endothelial cells from the
flowing blood). Levels of red blood cell (RBC) velocities are
about 300𝜇m/sec to 750 𝜇m/sec for 2-5 dpf embryos [42].
Therefore, movies should be recorded at high speeds for
further analysis.
In 2010, Noldus introduced the DanioVison system
(Noldus Information Technology, NL), which consists of the
DanioVison chamber for recording the behaviour of larval
zebrafish, and the software platform, EthoVision XT9.0, for
analyzing the data. EthoVision has a flexible data analysis
module, and separately acquired movies can be loaded into
the software enabling automated analysis of larvae and adult
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Figure 2: View point’s ZebraLab software user interface.
Figure 3: DanioScope system and EthoVision XT9.0 analysis platform. A. DanioScope recognizes the embryos and can analyze videos with
multiple animals simultaneously and DanioScope reports back (table A) the following parameters: burst activity (percentage of time the
embryo was moving), Inactivity (percentage of time of inactivity); burst duration (total time spent active); inactivity duration (total time
spent inactive); burst count (number of times the embryo moved); Burst count/per minute. B. DanioScope measures activity in the heart of
each larvae, from this activity the heartbeat in beats per second or per minute is extracted graph B. C. Flow activity can be measured in both
blood vessels and the gut.
zebrafish behaviour. Noldus introduced a wide range of tools
for all kinds of behavioural tests for zebrafish. The software is
used to measure the activity, heartbeat, morphology and flow
in embryos and larvae while the video tracking is designed to
analyze the movement of adults in several learning, anxiety,
or social behaviour paradigms (Figure 3).
Zcardio (ZeClinics, Spain) has such applications. For
example, Zcardio is developed formyocardial fluorescent fish
and the software enables for the detection of the following
dysfunctions: beat frequency (ventricle and atrium), arrhyth-
mias, QT & QTc interval, fibrillation, ejection fraction, vein
blood flow velocity, artery blood flow velocity, and cardiac
arrest [43, 44].
3.2. Molecular Assessment of Cardiotoxicity. Gene expression
profiling may aid in the extrapolation of compound-induced
effects for cardiotoxicity investigation, because of the conser-
vation of the molecular pathways and mechanisms between
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zebrafish and human. In addition to its utility in screening,
zebrafish chemical genetics can also help analyze the target
and mechanism of action of a test compound through
chemical rescue experiments, knockdowns, and phenotype
comparisons. Zebrafish are uniquely qualified for use in
large-scale screening and the availability of numerous genetic
tools facilitates the detailed study of candidate drug effects
in vivo [32, 45], prior to preclinical testing in mammalian
models. The zebrafish chemical genetic screen is a time and
cost-effective method for direct in vivo drug discovery and
serves as an advanced system in drug development [46].
Zebrafish gene expression can be analyzed using tools such as
quantitative real-time polymerase chain reaction (qRT-PCR)
[47] and in situ hybridization [48]. RNA extraction, followed
by RNA microarray analysis is available for gene expres-
sion profiling [49]. Western blot and immunohistochemistry
can determine the protein expression profiles. Examples
of genes or markers (Cardiotoxic genes/proteins) that are
screened in cardiotoxicity studies include SLC28A3, RARG,
and UGT1A6 [50]. Genetic variants in other genes include
the following: ABCC1,2,5 CBR3, CAT, RAC2, HAS3, NCF4,
GSTP1, SULT2B1, ABCB1,4, POR, HFE, HAS3, SCL22A17 and
NOS3 [51, 52]
4. Zebrafish Cardiotoxicity Studies
The zebrafish embryo has been used to assess the impact
of exposure of environmental pollutants including Dioxins,
PAHs, PBDEs, AChEIs, as well as nanoparticles [53] alcohols
[54, 55], and recreational drugs such as Cocaine [56], or
Cigarette smoke [57] on the cardiovascular system. Soanes et
al. studied the effect of different products of cigarettes on 24
to 48-hpf zebrafish embryos [57]. It was found that zebrafish
heartbeat was reduced by 50% at 48-hpf after being exposed
to cigarettes [57].Moreover, continual alcohol exposure (until
2-3 dpf) has been shown to alter the heart of zebrafish
functionally and morphologically [58].
Zebrafish was also utilized as a model to assess the
cardiotoxicity of several clinical drugs. For instant, car-
diotoxicity evaluation of anti-cancer drugs is frequently
performed in zebrafish [59]. Cancer patients usually suffer
the complications of chemotherapy due to its cardiotoxic
effect [55]. Cardiotoxicity has been linked to the morbidity
and mortality of cancer patients [60–62], that being said,
it can be minimized by accurately identifying the high-
risk patients. Identification of patients at high risk can be
accomplished through the discovery of new biomarkers.
Existing screening methods do not give sufficient results to
aid in disease prognosis. In the process of treating cancer with
chemotherapy, the cardiological conditions must be consid-
ered [63]; this is absent in the current guidelines for cancer
treatment. Mostly, chemotherapeutic agents have significant
side effects on cardiovascular system which can be prevented
by identifying new compounds such as antioxidants and
endothelial- or cardiomyocyte-protective agents [60]. Below
we explain current findings for the cardiotoxicities of tested
agents on zebrafish [64].
4.1. Clinical Drug-Induced Cardiotoxicity. One of the
widely used anticancer drugs belongs to the Anthracyclines
(ANTs) class; Daunorubicin, Pirarubicin, Doxorubicin
(DOX), Epirubicin, and DOX-liposome. Han et al. exposed
zebrafish embryos to a variety of ANTs that resulted in
incomplete looping of the heart tube, pericardial edema and
bradycardia in dose-dependent manner [25]. The greatest
defect was produced by DOX, whereas Daunorubicin
produced the minimum toxicity. ANTs have been shown
to downregulate the genes and protein expression related
to cardiac development. The ANTs’ cardiotoxic effect in
the zebrafish model were similar to that reported in other
mammalian models [25, 55].
Zhu, et al. showed that zebrafish exhibited pericardial
edema and circulatory disturbance in response to car-
diotoxic drugs [26]. Seven known human cardiotoxic drugs
were tested in the zebrafish model. These included aspirin,
clomipramine hydrochloride, cyclophosphamide, nimodip-
ine, quinidine, terfenadine, and verapamil hydrochloride
[65]. Aspirin is known to known to elevate the heart rate,
and other drugs are known to cause bradycardia. Drugs were
administered via soaking or yolk sac microinjection. After 4
and 24 h post-drug treatment, the cardiotoxicity was assessed
based on six cardiac parameters: heart rate, heart rhythm,
pericardial edema, circulation, hemorrhage, and thrombosis.
Evaluation of the effect of human drugs on zebrafish heart led
to the conclusion that the effect of these drugs on human and
zebrafish are comparable which validated the zebrafish as an
excellent model for studying the drug cardiotoxicity [65].
Furthermore, Louis J. D’Amico et al. described methods
that are used on the zebrafish for evaluating drug-induced
cardiotoxicity [60, 66]. Several drugs from different cate-
gories (vancer drugs, antiarrhythmic, anticonvulsant, and
beta-blockers) are known to affect the heart function in
patients were tested. These drugs included 5-fluorouracil
and mitoxantrone, as well as above metnioned drugs; DOX,
Cyclophosphamide terfenadine. Drug concentrations rang-
ing from 0.01𝜇M to 1000𝜇M were administered to 2 dpf
zebrafish embryos for 24 hr. The cardiotoxicity was assessed
by measuring the heart rate, heart rhythm, circulation and
morphological changes. This study showed similar results
as previous [25, 65]; DOX and Cyclophosphamide caused
bradycardia while Terfenadine and Clomipramine, which are
known to cause a prolongation in QT interval in human [67],
induced pericardial edema and hemorrhage in zebrafish.
Antibiotics and antiviral drugs such as Gentamicin, Aman-
tadine and Tetracycline rarely induce cardiotoxic effect in
humans. These are usually used as a negative control in
zebrafish cardiotoxicity studies [68], and as expected they
did not induce any cardiac effect in zebrafish [66]. The
results were conclusive in employing the zebrafish model
for studying drug-induced cardiotoxicity [69, 70]. Table 1
summarizes some findings from this study [66].
Additionally, Cheng et al. assessed the cardiotoxicity of
some kinase inhibitors that are used clinically in cancer
treatment in zebrafish. The kinase inhibitor, Sorafenib, has
been associated with significant declines in ejection fraction
in 13% of treated patients [71]. Zebrafish Sorafenib exposure
was compared to two kinase inhibitors, Sunitinib that is
known to possess cardiotoxic effect and Gefitinib that has
no cardiotoxic effect. Zebrafish treatment with Sorafenib and
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Table 1: Comparison of cardiotoxicities for several clinical drugs on human and zebrafish.
Drug Effect on human Effect on zebrafish
Doxorubicin [25]
5-fluorouracil
Terfenadine [26]
Lidocaine
Cardiomyopathy, arrhythmia, negative inotropic
effects (affect the muscle contraction), or QT
prolongation.
Bradycardia, Acute atrioventricular block (AV block),
Slow circulation
Clomipramine
[26] QT prolongation
Pericardial edema, hemorrhage, bradycardia, and death
at higher concentrations
Quinidine QT prolongation AV block
Thioridazine
Metoprolol [26] Bradycardia Pericardial edema
Mexiletine Decreased heart rate Decreased heart rate
Phenytoin
Sunitinib at 5 mol/L induced cardiotoxicity evident by cardiac
impairment that was presented with pericardial edema and
reduced contractile function. Gefitinib did not result in
cardiotoxicity
Moreover, Fang et al. assessed the cardiotoxicity of
three addictive drugs, Methamphetamine, Ketamine, and
Methadone, in zebrafish embryos [72]. Exposure to 1000mg/
L ofMethamphetamine for 12 hours resulted in cardiotoxicity
evident with pericardial edema, cardiac looping defects
and decreased heart rate in zebrafish. Treatment with the
same dose of Ketamine resulted in decreased heart rate.
Interestingly, Methadone was lethal at 500mg/L, while treat-
ment with 100mg/L resulted in severe circulation abnor-
malities and pericardial edema. According to these results,
Methadone is the most cardiotoxic agents among the three.
Based on this data, it was suggestive to advise the clinicians
to periodically check the cardiac function of patients treated
with these drugs [72].
A study was performed by Cornet et al. to test the
toxicity of 24 drugs on zebrafish embryos [24]. Embryos
treated with 10 𝜇M haloperidol, known to be cardiotoxic in
zebrafish and humans [73], for 4 hrs, were considered as
positive controls. Videos were taken under a microscope
and ZeCardio software (ZeClinics) was used to extract
different cardiac parameters; heart rate, cardiac arrest, QTc
prolongation, and ejection fraction (EJF). Eight compounds
out of the twenty four (i.e., haloperidol, cisapride, docetaxel,
dofetilide, pindolol, riluzole, trifluoperazine HCL, and vin-
cristine), showed a decrease in the heart rate (bradycardia)
and promoted cardiac arrests. In contrast, zebrafish embryos
treated with ciprofloxacin and d-glucose showed increased
heart rates but no change in the cardiac arrest. Prolongation
in the QTc interval was observed in larvae treated with
haloperidol and pindolol. However, a shorter QTc interval
was observed in the embryos treated with ciprofloxacin and
d-glucose. Figure 4 represents the findings from the study.
Finally, diethyl-aminobenzaldehyde (DEAB) is a drug
that we use as a positive control in the toxicological studies
in our zebrafish lab at Qatar University Biomedical Research
Center. Embryos were incubated from 24-hpf to 96-hpf
with 10𝜇M and 100𝜇M of DEAB. Figure 5, shows some
cardiological and teratogenic effects after exposure to DEAB.
4.2. Cardiotoxic Nanoparticles. Nanotechnology is a multi-
trillion-dollar business sector that has an increasing impact
on the industrial revolution. Nanoparticles have great poten-
tial to be used as drug carriers against human diseases.
Zebrafish has been proposed as one of the most successful
model and notable advancement in nanotoxicological studies
[74]. For instance, at high concentration, gold and silver
nanoparticles were shown to change the cardiac morphology
in zebrafish [55]. One study has assessed the cardiotoxicity
effect of silica nanoparticles using the zebrafish model [75].
Silica nanoparticles have gained great interest for its extensive
applications includingmedical diagnostics, drug delivery and
gene therapy [75]. Zebrafish embryos were exposed to silica
nanoparticles for continuing exposure period (24 - 96 hpf)
to assess the toxicity of silica nanoparticles (embryonic
mortality and malformation, cellular death assay). Heart
rate was measured at 24 and 48-hpf; significant bradycardia
was reported with embryos treated with 100 and 200 𝜇g/mL
concentrations compared to lower concentrations of silica
nanoparticles and the negative control. In addition to the
heart rate measurement, the expression of cardiovascular-
related proteins by western blot analysis was used as another
approach to assess the cardiotoxic effect of silica nanopar-
ticles. Exposure of the embryos to silica nanoparticles did
not cause any significant change in vascular endothelial
growth factor receptor 2 (VEGFR2). In contrast, phospho-
rylated VEGFR2 and angiogenesis-related ERK1/2 expres-
sion were inhibited in a dose-dependent manner. Moreover,
phosphorylated ERK1/2 expression was inhibited completely.
However, no significant changes were observed in ERK1/2,
MEF2C/ NKX2.5, and 𝛽-actin.
Chitosan is a well-known biopolymer that has a wide
range of applications including growth inhibition of wide
varieties of bacteria and spoilage microorganisms [76].
Recently, our group has shown that chitosan zinc oxide
(ZnO) nanoparticles (90% chitosan: 10%ZnO) has inhibitory
effect on sulfur reducing bacteria. In the same study and
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Figure 4: Cardiotoxicity evaluation results adapted fromCornet et al. [24]. (a) Scheme of the experimental process; (b) bar charts representing
the heart beat frequency in beats per minute (bpm); (c) QT corrected interval (QTc); (d) ejection fraction (EJF); (e) and longest cardiac arrest
of 100 h old zebrafish larvae.
(a) (b) (c)
Figure 5: Magnification X= .63. Typical phenotype of a zebrafish embryo incubated from 24-hpf to 96-hpf in (a) embryo medium as a
negative control, in (b) 10𝜇m diethyl-aminobenzaldehyde (DEAB), and in (c) 100𝜇m DEAB. Note the deformed embryos in DEAB: short
size, scoliosis, yolk, and heart edema (black arrows).
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using zebrafish, we showed that these nanoparticles were
generally “Green” [77]. In other words, according to Acute
Toxicity Rating Scale by Fish and Wildlife Service, Chi-
tosan zinc oxide nanoparticles were regarded as practically
nontoxic with LC50 more than 100𝜇g/mL [78]. The car-
diotoxic effects of two nanoparticles were also tested in our
zebrafish lab (unpublished results). In these studies, we used
Tg[cmlc:GFP] transgenic AB strain, expressing GFP in their
cardiac myocyte, to allow good quality of cardiac imaging
for heart function assessment. At 96-hpf, we incubated the
embryos for 4 hrs. at 28.5∘C with (i) the negative control
0.1% DMSO (ii) the positive control 10 𝜇M haloperidol,
(iii) 200 𝜇g/mL ChNP, and (iv) 200 𝜇g/mL CZNC. Embryos
were then anesthetized by immersion in 0.7 𝜇M Tricaine
methanesulfonate and positioned under the microscope to
record the videos. We measured the time length of ventricle
beat, atrial and ventricular fibrillation, cardiac arrest, ejection
fraction [(Ef %) = ((DD-SD)/DD) x100]; DD is the ventricle
diastolic diameter (max dilatation); SD is the ventricle systolic
diameter (max contraction). For calculation of the QTc inter-
val (linearly correctedQT interval), the Framingham formula
(QTc = QT + 0.154 (1 − RR)) was adjusted for zebrafish as
QTc = QT + 0.154 (2.66 − RR). RR = 6.6ms/measured bpm is
applied embryos treated with haloperidol showed significant
bradycardia and a significant increase in the cardiac arrest
compared to the negative control. In contrast, haloperidol-
treated embryos showed no significant effect on the ejection
fraction, which is expected as there is no evidence in the
literature showing that haloperidol causes any significant dif-
ference on the ejection fraction. Moreover, embryos treated
with haloperidol showed significant Arrhythmia, which was
indicated by increase in the percentage of beats defect on the
atriumand ventricle compared to the negative control. On the
other hand, embryos treated with ChNP and CZNCs showed
no significant changes on the heart beats, ejection fraction,
percentage of beats defect and cardiac arrest compared to the
negative control.
5. Conclusions and Future Directions
Because of the conservation between zebrafish and human
cardiogenesis, as well as the other advantages such as cost,
rapid development, transparency, simple maintenance/egg
collection, and ability for survival without a fully functional
cardiovascular system, zebrafish became a common model
system for cardiovascular disease. As summarized in the
previous section, zebrafish models also play a key role in
testing different drug cardiotoxicities. The zebrafish model
is well conserved and can serve into drug development
as a preclinical requirement that can decipher drug safety
concerns in patients. Future studies are necessary to uncover
the molecular targets of each tested chemical in zebrafish
in relevance to cardiac genes/proteins. In each case, an
investigation must be done of the known molecular targets
of the compound. In addition, the evaluation of whether the
compound affects pathways that are known to cause similar
phenotypes upon disruption. Finally, if these approaches are
not fruitful, a broader search may be needed for novel targets
of each compound that are responsible for their effects during
cardiovascular development.
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